Know Cancer

forgot password

Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients

Phase 4
18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients

In approximately 20% of patients who are considered for accelerated partial breast
irradiation (APBI), the balloon-to-skin distance ranges from 3-6 mm. The Contura applicator
has 5 source lumens. In contrast, the MammoSite catheter has a single source lumen. The
ability to choose from multiple source lumens with the Contura catheter allows one to avoid
a radiation "hot spot" in the skin in cases where the balloon-to-skin spacing is only 3-6

Another limitation of the MammoSite catheter is that one cannot improve on the suboptimal
conformance of the balloon with the surrounding breast tissue. An air/fluid pocket next to
the balloon can push breast tissue at greatest risk of harboring residual disease away from
the radioactive source. With APBI, the planning target volume for plan evaluation
(PTV_EVAL) is defined as the breast tissue volume bounded by uniform expansion of the
balloon radius in all dimensions by 10 mm less the balloon volume. PTV_EVAL is limited to 5
mm from the skin surface and by the posterior breast tissue extent (chest wall and
pectoralis muscles are excluded). The volume of an air/fluid pocket is usually 4.8% ± 1.1%
(mean ± standard error) of PTV_EVAL. The Contura applicator has a vacuum lumen with 2
openings adjacent to the balloon that allow for air/fluid removal. By using the vacuum
lumen on a Contura applicator, one can typically decrease the size of an air/fluid pocket by
about one third. In approximately 90% of Contura patients, the volume of an air/fluid
pocket around the balloon can be reduced to less than or equal to 3.0% of PTV_EVAL. In
contrast, the volume of an air/fluid pocket around the balloon is less than or equal to 3.0%
of PTV_EVAL in only about half of MammoSite patients. Since this study addresses
intermediate-risk patients, it is particularly important that the size of an air/fluid
pocket be minimized with a Contura applicator.

SenoRx, Inc. (Aliso Viejo, CA) is currently conducting a registry study of the Contura MLB
applicator in the "low-risk" patient population. This "intermediate-risk" study is
complimentary to the low-risk registry study. There is no overlap in patient eligibility.
Intermediate-risk patients meet any of the following criteria:

1. Age 18-49 years, or

2. Estrogen receptor-negative and progesterone receptor-negative breast cancer, or

3. 1-3 involved axillary lymph nodes

Inclusion Criteria:

- Patients with invasive breast cancer are required to have axillary staging which can
include sentinel node biopsy alone if sentinel node is negative or axillary
dissection or sampling with a minimum total of 6 axillary nodes if sentinel node is
positive. Axillary staging is not required for patients with DCIS.

- Estrogen receptor (ER) and progesterone receptor (PR) analysis must be negative.

- The patient must be ≥ 18 years old.

- If the patient is older than 49 years, she must meet at least one of the following 2

i. 1-3 histologically positive axillary nodes ii. negative ER and PR analysis

- The patient should have a life expectancy of at least 10 years, excluding her
diagnosis of breast cancer.

- The tumor must be DCIS or invasive adenocarcinoma of the breast.

- Gross disease must be unifocal with pathologic tumor size 3.0 cm or less. Patients
with microscopic multifocality are eligible as long as total pathologic tumor size is
3.0 cm or less.

- The patient must have pathological stage 0, I, or II breast cancer.

- Surgical treatment of the breast must have been lumpectomy. The margins of the
resected specimen must be histologically free of tumor (DCIS and invasive).
Re-excision of surgical margins is permitted.

- The patient must be registered within 42 days following the last surgery for breast

- The target lumpectomy cavity/whole breast reference volume must be ≤ 30% based on the
postoperative CT scan.

Exclusion Criteria:

- The patient is < 18 years old.

- If the patient is older than 49 years, she has both an ER and PR positive tumor and
histologically negative axillary nodes.

- T2 (> 3.0 cm), T3, stage III, or stage IV breast cancer.

- "Marginal" or "borderline" ER or PR analysis results.

- More than 3 histologically positive axillary nodes.

- Axillary nodes with definite evidence of microscopic or macroscopic extracapsular

- One or more positive non-axillary sentinel node(s). Intramammary nodes are staged as
axillary nodes.

- Non-epithelial breast malignancies such as sarcoma or lymphoma.

- Proven multicentric carcinoma in more than one quadrant or separated by 4 or more

- Paget's disease of the nipple.

- Synchronous bilateral invasive or non-invasive breast cancer.

- History of DCIS or invasive breast cancer.

- Surgical margins that cannot be microscopically assessed or are positive at
pathologic evaluation.

- Clear delineation of the target lumpectomy cavity not possible.

- Any treatment with radiation therapy, chemotherapy, and/or biotherapy administered
for the currently diagnosed breast cancer prior to registration. The only exception
is hormonal therapy, which may have been given for no more than a total of 28 days
anytime after diagnosis and before registration.

- Prior breast or thoracic radiotherapy for any condition.

- Collagen vascular disease, specifically dermatomyositis with a CPK level above normal
or with an active skin rash, systemic lupus erythematosis, or scleroderma.

- Pregnancy or lactation at the time of proposed registration. Women of reproductive
potential must agree to use an effective non-hormonal method of contraception during

- Psychiatric or addictive disorders.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum skin dose is less than or equal to 100% of the prescribed radiation dose and air/fluid pocket next to the balloon is less than or equal to 3.0% of the planning target volume for plan evaluation

Outcome Time Frame:

19 months

Safety Issue:


Principal Investigator

Richard B Wilder, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Center of Irvine


United States: Institutional Review Board

Study ID:




Start Date:

October 2007

Completion Date:

December 2009

Related Keywords:

  • Breast Cancer
  • Contura
  • Cancer
  • Accelerated
  • Partial
  • Breast
  • Irradiation
  • Breast Neoplasms



Cancer Center of Irvine Irvine, California  92618